Key Fields

Sequence Number:

Date Received: __ __ __ __ - __ __- __ __

CIBMTR Center Number:

CIBMTR Research ID:

Event date: __ __ __ __ - __ __- __ __

Subsequent Transplant or Cellular Therapy

Is this the report of a second or subsequent transplant or cellular therapy for the same disease?

Yes No

Disease Assessment at Diagnosis Questions: 1 - 13

Is the disease (AML) therapy related? (not MDS / MPN)

yes no Unknown

1

Specify prior disease2

Breast cancer

Hodgkin lymphoma

Non-Hodgkin lymphoma

Other disease (malignant or nonmalignant)

Specify other prior disease:3

Date of diagnosis of prior disease

Known Unknown

4

Date of diagnosis of prior disease:5 __ __ __ __ - __ __- __ __

Cytotoxic therapy

Yes No Unknown

6

Radiation

yes no Unknown

7

Other therapy (e.g. immunotherapy, cellular therapy, etc.)

yes no Unknown

8

Specify other therapy:9

Did the recipient have a documented antecedent hematologic disorder? (myelodysplastic syndrome or myeloproliferative neoplasm)

yes no Unknown

10

What was the date of diagnosis of antecedent hematologic disorder?11 __ __ __ __ - __ __- __ __

What was the classification of the antecedent hematologic disorder at diagnosis?12

Refractory cytopenia with unilineage dysplasia (RCUD) (includes refractory anemia (RA)) (51)

Refractory anemia with ringed sideroblasts (RARS) (55)

Refractory anemia with excess blasts-1 (RAEB-1) (61)

Refractory anemia with excess blasts-2 (RAEB-2) (62)

Refractory cytopenia with multilineage dysplasia (RCMD) (64)

Childhood myelodysplastic syndrome (Refractory cytopenia of childhood (RCC)) (68)

Myelodysplastic syndrome with isolated del(5q) (5q– syndrome) (66)

Myelodysplastic syndrome (MDS), unclassifiable (50)

Chronic neutrophilic leukemia (165)

Chronic eosinophilic leukemia, NOS (166)

Essential thrombocythemia (includes primary thrombocytosis, idiopathic thrombocytosis, hemorrhagic thrombocythemia) (58)

Polycythemia vera (PCV) (57)

Primary myelofibrosis (includes chronic idiopathic myelofibrosis (CIMF), angiogenic myeloid metaplasia (AMM), myelofibrosis/sclerosis with myeloid metaplasia
(MMM), idiopathic myelofibrosis) (167)

Myeloproliferative neoplasm (MPN), unclassifiable (60)

Chronic myelomonocytic leukemia (CMMoL) (54)

Juvenile myelomonocytic leukemia (JMML, JCML, JCMML) (no evidence of Ph1 or BCR/ABL) (36) Also complete CIBMTR Form 2015 - JMML

Atypical chronic myeloid leukemia, Ph-/bcr/abl- (CML, NOS) (45)

Atypical chronic myeloid leukemia, Ph-/bcr unknown (CML, NOS) (46)

Atypical chronic myeloid leukemia, Ph unknown/bcr- (CML, NOS) (48)

Atypical chronic myeloid leukemia, Ph unknown/bcr unknown (CML, NOS) (49)

Myelodysplastic / myeloproliferative neoplasm, unclassifiable (69) Also complete CIBMTR Form 2014 - MDS/MPN

Aplastic anemia (300) Also complete CIBMTR Form 2028 - APL

Fanconi anemia (311) Also complete CIBMTR Form 2029 – FA

Shwachman-Diamond (305)

Diamond-Blackfan anemia (pure red cell aplasia) (312)

Dyskeratosis congenita (307)

Other antecedent hematologic disorder

Specify other antecedent hematologic disorder:13

Laboratory Studies at Diagnosis Questions: 14 - 31

WBC

Known Unknown

14

15 x 109/L (x 103/mm3)

x 106/L

Date sample collected:16 __ __ __ __ - __ __- __ __

Blasts in blood

Known Unknown

17

18 %

Date sample collected:19 __ __ __ __ - __ __- __ __

Blasts in bone marrow

Known Unknown

20

21 %

Date sample collected:22 __ __ __ __ - __ __- __ __

Was extramedullary disease present?

yes no Unknown

23

Central nervous system

yes no

24

Cerebrospinal fluid (CSF)

Yes No

25

Parenchyma (brain)

Yes No

26

Skin

yes no

27

Soft tissue (soft tissue mass / granulocytic sarcoma)

yes no

28

Testes / ovaries

Yes No

29

Other site

yes no

30

Specify other site:31

Pre-HCT or Pre-Infusion Therapy Questions: 32 - 68

Was therapy given?

yes no

32

Line of Therapy (1) Questions: 33 - 68

Purpose of therapy33

Induction

Consolidation

Maintenance

treatment for disease relapse

Intrathecal therapy

yes no

34

Systemic therapy

yes no

35

Date therapy started

Known Unknown

36

Date started:37 __ __ __ __ - __ __- __ __

Date therapy stopped

Known Unknown

38

Date stopped:39 __ __ __ __ - __ __- __ __

Number of cycles

Known Unknown Not Applicable

40

Number of cycles:41

Specify systemic therapy: (check all that apply for this line of therapy)

Azacytidine

All-trans retinoic acid

Arsenic

Cladribine

Clofarabine

Cytarabine (Ara ­ C) ≤ 10 g/m2/cycle

cytarabine (Ara - C) > 10 g/m2/cycle

Daunorubicin

Decitabine

Etoposide

Fludarabine

Gemtuzumab

Idarubicin

Midostaurin

Mitoxantrone

Sorafenib

Thioguanine

Other systemic therapy

42

(Vidaza)

(Tretinoin)

(2-CDA, Leustatin)

(Cerubidine)

(Dacogen) 

(VP-16, VePesid)

(Fludara)

(Mylotarg)

(Idamycin)

(Novantrone)

(6-TG)

Specify months of therapy:43  (Azacytidine (Vidaza))

Specify months of therapy:44  (Decitabine (Dacogen))

Specify months of therapy:45 (Sorafenib)

Specify other systemic therapy:46

Radiation therapy

yes no

47

Date therapy started

Known Unknown

48

Date started:49 __ __ __ __ - __ __- __ __

Date therapy stopped

Known Unknown

50

Date stopped:51 __ __ __ __ - __ __- __ __

Central nervous system

yes no

52

Other site

yes no

53

Specify other site:54

Cellular therapy55

yes - Also complete Pre-CTED Form 4000

no

Best response to line of therapy56

Complete
remission
(CR)

– All of the following response criteria without progression for at least four weeks: < 5% blasts in the bone marrow, no blasts with Auer rods, 
no extramedullary disease (e.g., central nervous system or soft tissue involvement),  ANC of ≥ 1,000/µL, Platelets ≥ 100,000/ µL

Complete remission with incomplete hematologic recovery
(CRi)

- All CR criteria except for residual neutropenia (<1000/µl) and/or thrombocytopenia
(<100,000/µl)

No complete remission

Date assessed:57 __ __ __ __ - __ __- __ __

Was the recipient MRD negative following this line of therapy?

Yes No

58

Did the recipient relapse following this line of therapy?

yes no

59

Date of relapse:60 __ __ __ __ - __ __- __ __

Central nervous system

yes no

61

Cerebrospinal fluid (CSF)

Yes No

62

Parenchyma (brain)

Yes No

63

Skin

yes no

64

Soft tissue (soft tissue mass / granulocytic sarcoma)

yes no

65

Testes / ovaries

Yes No

66

Other site

yes no

67

Specify other site:68

Laboratory Studies at Last Evaluation Prior to the Start of the Preparative Regimen / Infusion Questions: 69 - 96

WBC

Known Unknown

69

70 x 109/L (x 103/mm3)

x 106/L

Date sample collected:71 __ __ __ __ - __ __- __ __

Blasts in blood

Known Unknown

72

73 %

Date sample collected:74 __ __ __ __ - __ __- __ __

Blasts in bone marrow

Known Unknown

75

76 %

Date sample collected:77 __ __ __ __ - __ __- __ __

Specify method of assessment

Flow cytometry Morphology

78

Was flow cytometry performed?

yes no Unknown

79

Blood

yes no

80

Date sample collected:81 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

82

Specify percent disease detected:83 %

Bone marrow

yes no

84

Date sample collected:85 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

86

Specify percent disease detected:87 %

Was extramedullary disease present?

yes no Unknown

88

Central nervous system

yes no

89

Cerebrospinal fluid (CSF)

Yes No

90

Parenchyma (brain)

Yes No

91

Skin

yes no

92

Soft tissue (soft tissue mass / granulocytic sarcoma)

yes no

93

Testes / ovaries

Yes No

94

Other site

yes no

95

Specify other site:96

First Name:

Last Name:

E-mail address:

Date: __ __ __ __ - __ __- __ __

Specify therapy for prior disease:

Specify site(s) of disease:

Specify site(s) of radiation therapy:

Specify site(s) of disease relapse:

Specify tissue and results at last evaluation prior to the start of the preparative regimen / infusion:

Specify site(s) of disease:

Center: CRID: 

Form 2010 R4.0: Acute Myelogenous Leukemia (AML) Pre-Infusion Data

CIBMTR Form 2010 revision 4.0 last updated Monday, July 17, 2017
Copyright(c) 2012 National Marrow Donor Program and

The Medical College of Wisconsin, Inc. All rights reserved. Page 1 / 5



Key Fields

Sequence Number:

Date Received: __ __ __ __ - __ __- __ __

CIBMTR Center Number:

CIBMTR Research ID:

Event date: __ __ __ __ - __ __- __ __

Subsequent Transplant or Cellular Therapy

Is this the report of a second or subsequent transplant or cellular therapy for the same disease?

Yes No

Disease Assessment at Diagnosis Questions: 1 - 13

Is the disease (AML) therapy related? (not MDS / MPN)

yes no Unknown

1

Specify prior disease2

Breast cancer

Hodgkin lymphoma

Non-Hodgkin lymphoma

Other disease (malignant or nonmalignant)

Specify other prior disease:3

Date of diagnosis of prior disease

Known Unknown

4

Date of diagnosis of prior disease:5 __ __ __ __ - __ __- __ __

Cytotoxic therapy

Yes No Unknown

6

Radiation

yes no Unknown

7

Other therapy (e.g. immunotherapy, cellular therapy, etc.)

yes no Unknown

8

Specify other therapy:9

Did the recipient have a documented antecedent hematologic disorder? (myelodysplastic syndrome or myeloproliferative neoplasm)

yes no Unknown

10

What was the date of diagnosis of antecedent hematologic disorder?11 __ __ __ __ - __ __- __ __

What was the classification of the antecedent hematologic disorder at diagnosis?12

Refractory cytopenia with unilineage dysplasia (RCUD) (includes refractory anemia (RA)) (51)

Refractory anemia with ringed sideroblasts (RARS) (55)

Refractory anemia with excess blasts-1 (RAEB-1) (61)

Refractory anemia with excess blasts-2 (RAEB-2) (62)

Refractory cytopenia with multilineage dysplasia (RCMD) (64)

Childhood myelodysplastic syndrome (Refractory cytopenia of childhood (RCC)) (68)

Myelodysplastic syndrome with isolated del(5q) (5q– syndrome) (66)

Myelodysplastic syndrome (MDS), unclassifiable (50)

Chronic neutrophilic leukemia (165)

Chronic eosinophilic leukemia, NOS (166)

Essential thrombocythemia (includes primary thrombocytosis, idiopathic thrombocytosis, hemorrhagic thrombocythemia) (58)

Polycythemia vera (PCV) (57)

Primary myelofibrosis (includes chronic idiopathic myelofibrosis (CIMF), angiogenic myeloid metaplasia (AMM), myelofibrosis/sclerosis with myeloid metaplasia
(MMM), idiopathic myelofibrosis) (167)

Myeloproliferative neoplasm (MPN), unclassifiable (60)

Chronic myelomonocytic leukemia (CMMoL) (54)

Juvenile myelomonocytic leukemia (JMML, JCML, JCMML) (no evidence of Ph1 or BCR/ABL) (36) Also complete CIBMTR Form 2015 - JMML

Atypical chronic myeloid leukemia, Ph-/bcr/abl- (CML, NOS) (45)

Atypical chronic myeloid leukemia, Ph-/bcr unknown (CML, NOS) (46)

Atypical chronic myeloid leukemia, Ph unknown/bcr- (CML, NOS) (48)

Atypical chronic myeloid leukemia, Ph unknown/bcr unknown (CML, NOS) (49)

Myelodysplastic / myeloproliferative neoplasm, unclassifiable (69) Also complete CIBMTR Form 2014 - MDS/MPN

Aplastic anemia (300) Also complete CIBMTR Form 2028 - APL

Fanconi anemia (311) Also complete CIBMTR Form 2029 – FA

Shwachman-Diamond (305)

Diamond-Blackfan anemia (pure red cell aplasia) (312)

Dyskeratosis congenita (307)

Other antecedent hematologic disorder

Specify other antecedent hematologic disorder:13

Laboratory Studies at Diagnosis Questions: 14 - 31

WBC

Known Unknown

14

15 x 109/L (x 103/mm3)

x 106/L

Date sample collected:16 __ __ __ __ - __ __- __ __

Blasts in blood

Known Unknown

17

18 %

Date sample collected:19 __ __ __ __ - __ __- __ __

Blasts in bone marrow

Known Unknown

20

21 %

Date sample collected:22 __ __ __ __ - __ __- __ __

Was extramedullary disease present?

yes no Unknown

23

Central nervous system

yes no

24

Cerebrospinal fluid (CSF)

Yes No

25

Parenchyma (brain)

Yes No

26

Skin

yes no

27

Soft tissue (soft tissue mass / granulocytic sarcoma)

yes no

28

Testes / ovaries

Yes No

29

Other site

yes no

30

Specify other site:31

Pre-HCT or Pre-Infusion Therapy Questions: 32 - 68

Was therapy given?

yes no

32

Line of Therapy (1) Questions: 33 - 68

Purpose of therapy33

Induction

Consolidation

Maintenance

treatment for disease relapse

Intrathecal therapy

yes no

34

Systemic therapy

yes no

35

Date therapy started

Known Unknown

36

Date started:37 __ __ __ __ - __ __- __ __

Date therapy stopped

Known Unknown

38

Date stopped:39 __ __ __ __ - __ __- __ __

Number of cycles

Known Unknown Not Applicable

40

Number of cycles:41

Specify systemic therapy: (check all that apply for this line of therapy)

Azacytidine

All-trans retinoic acid

Arsenic

Cladribine

Clofarabine

Cytarabine (Ara ­ C) ≤ 10 g/m2/cycle

cytarabine (Ara - C) > 10 g/m2/cycle

Daunorubicin

Decitabine

Etoposide

Fludarabine

Gemtuzumab

Idarubicin

Midostaurin

Mitoxantrone

Sorafenib

Thioguanine

Other systemic therapy

42

(Vidaza)

(Tretinoin)

(2-CDA, Leustatin)

(Cerubidine)

(Dacogen) 

(VP-16, VePesid)

(Fludara)

(Mylotarg)

(Idamycin)

(Novantrone)

(6-TG)

Specify months of therapy:43  (Azacytidine (Vidaza))

Specify months of therapy:44  (Decitabine (Dacogen))

Specify months of therapy:45 (Sorafenib)

Specify other systemic therapy:46

Radiation therapy

yes no

47

Date therapy started

Known Unknown

48

Date started:49 __ __ __ __ - __ __- __ __

Date therapy stopped

Known Unknown

50

Date stopped:51 __ __ __ __ - __ __- __ __

Central nervous system

yes no

52

Other site

yes no

53

Specify other site:54

Cellular therapy55

yes - Also complete Pre-CTED Form 4000

no

Best response to line of therapy56

Complete
remission
(CR)

– All of the following response criteria without progression for at least four weeks: < 5% blasts in the bone marrow, no blasts with Auer rods, 
no extramedullary disease (e.g., central nervous system or soft tissue involvement),  ANC of ≥ 1,000/µL, Platelets ≥ 100,000/ µL

Complete remission with incomplete hematologic recovery
(CRi)

- All CR criteria except for residual neutropenia (<1000/µl) and/or thrombocytopenia
(<100,000/µl)

No complete remission

Date assessed:57 __ __ __ __ - __ __- __ __

Was the recipient MRD negative following this line of therapy?

Yes No

58

Did the recipient relapse following this line of therapy?

yes no

59

Date of relapse:60 __ __ __ __ - __ __- __ __

Central nervous system

yes no

61

Cerebrospinal fluid (CSF)

Yes No

62

Parenchyma (brain)

Yes No

63

Skin

yes no

64

Soft tissue (soft tissue mass / granulocytic sarcoma)

yes no

65

Testes / ovaries

Yes No

66

Other site

yes no

67

Specify other site:68

Laboratory Studies at Last Evaluation Prior to the Start of the Preparative Regimen / Infusion Questions: 69 - 96

WBC

Known Unknown

69

70 x 109/L (x 103/mm3)

x 106/L

Date sample collected:71 __ __ __ __ - __ __- __ __

Blasts in blood

Known Unknown

72

73 %

Date sample collected:74 __ __ __ __ - __ __- __ __

Blasts in bone marrow

Known Unknown

75

76 %

Date sample collected:77 __ __ __ __ - __ __- __ __

Specify method of assessment

Flow cytometry Morphology

78

Was flow cytometry performed?

yes no Unknown

79

Blood

yes no

80

Date sample collected:81 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

82

Specify percent disease detected:83 %

Bone marrow

yes no

84

Date sample collected:85 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

86

Specify percent disease detected:87 %

Was extramedullary disease present?

yes no Unknown

88

Central nervous system

yes no

89

Cerebrospinal fluid (CSF)

Yes No

90

Parenchyma (brain)

Yes No

91

Skin

yes no

92

Soft tissue (soft tissue mass / granulocytic sarcoma)

yes no

93

Testes / ovaries

Yes No

94

Other site

yes no

95

Specify other site:96

First Name:

Last Name:

E-mail address:

Date: __ __ __ __ - __ __- __ __

Specify therapy for prior disease:

Specify site(s) of disease:

Specify site(s) of radiation therapy:

Specify site(s) of disease relapse:

Specify tissue and results at last evaluation prior to the start of the preparative regimen / infusion:

Specify site(s) of disease:

Center: CRID: 

Form 2010 R4.0: Acute Myelogenous Leukemia (AML) Pre-Infusion Data

CIBMTR Form 2010 revision 4.0 last updated Monday, July 17, 2017
Copyright(c) 2012 National Marrow Donor Program and

The Medical College of Wisconsin, Inc. All rights reserved. Page 2 / 5



Key Fields

Sequence Number:

Date Received: __ __ __ __ - __ __- __ __

CIBMTR Center Number:

CIBMTR Research ID:

Event date: __ __ __ __ - __ __- __ __

Subsequent Transplant or Cellular Therapy

Is this the report of a second or subsequent transplant or cellular therapy for the same disease?

Yes No

Disease Assessment at Diagnosis Questions: 1 - 13

Is the disease (AML) therapy related? (not MDS / MPN)

yes no Unknown

1

Specify prior disease2

Breast cancer

Hodgkin lymphoma

Non-Hodgkin lymphoma

Other disease (malignant or nonmalignant)

Specify other prior disease:3

Date of diagnosis of prior disease

Known Unknown

4

Date of diagnosis of prior disease:5 __ __ __ __ - __ __- __ __

Cytotoxic therapy

Yes No Unknown

6

Radiation

yes no Unknown

7

Other therapy (e.g. immunotherapy, cellular therapy, etc.)

yes no Unknown

8

Specify other therapy:9

Did the recipient have a documented antecedent hematologic disorder? (myelodysplastic syndrome or myeloproliferative neoplasm)

yes no Unknown

10

What was the date of diagnosis of antecedent hematologic disorder?11 __ __ __ __ - __ __- __ __

What was the classification of the antecedent hematologic disorder at diagnosis?12

Refractory cytopenia with unilineage dysplasia (RCUD) (includes refractory anemia (RA)) (51)

Refractory anemia with ringed sideroblasts (RARS) (55)

Refractory anemia with excess blasts-1 (RAEB-1) (61)

Refractory anemia with excess blasts-2 (RAEB-2) (62)

Refractory cytopenia with multilineage dysplasia (RCMD) (64)

Childhood myelodysplastic syndrome (Refractory cytopenia of childhood (RCC)) (68)

Myelodysplastic syndrome with isolated del(5q) (5q– syndrome) (66)

Myelodysplastic syndrome (MDS), unclassifiable (50)

Chronic neutrophilic leukemia (165)

Chronic eosinophilic leukemia, NOS (166)

Essential thrombocythemia (includes primary thrombocytosis, idiopathic thrombocytosis, hemorrhagic thrombocythemia) (58)

Polycythemia vera (PCV) (57)

Primary myelofibrosis (includes chronic idiopathic myelofibrosis (CIMF), angiogenic myeloid metaplasia (AMM), myelofibrosis/sclerosis with myeloid metaplasia
(MMM), idiopathic myelofibrosis) (167)

Myeloproliferative neoplasm (MPN), unclassifiable (60)

Chronic myelomonocytic leukemia (CMMoL) (54)

Juvenile myelomonocytic leukemia (JMML, JCML, JCMML) (no evidence of Ph1 or BCR/ABL) (36) Also complete CIBMTR Form 2015 - JMML

Atypical chronic myeloid leukemia, Ph-/bcr/abl- (CML, NOS) (45)

Atypical chronic myeloid leukemia, Ph-/bcr unknown (CML, NOS) (46)

Atypical chronic myeloid leukemia, Ph unknown/bcr- (CML, NOS) (48)

Atypical chronic myeloid leukemia, Ph unknown/bcr unknown (CML, NOS) (49)

Myelodysplastic / myeloproliferative neoplasm, unclassifiable (69) Also complete CIBMTR Form 2014 - MDS/MPN

Aplastic anemia (300) Also complete CIBMTR Form 2028 - APL

Fanconi anemia (311) Also complete CIBMTR Form 2029 – FA

Shwachman-Diamond (305)

Diamond-Blackfan anemia (pure red cell aplasia) (312)

Dyskeratosis congenita (307)

Other antecedent hematologic disorder

Specify other antecedent hematologic disorder:13

Laboratory Studies at Diagnosis Questions: 14 - 31

WBC

Known Unknown

14

15 x 109/L (x 103/mm3)

x 106/L

Date sample collected:16 __ __ __ __ - __ __- __ __

Blasts in blood

Known Unknown

17

18 %

Date sample collected:19 __ __ __ __ - __ __- __ __

Blasts in bone marrow

Known Unknown

20

21 %

Date sample collected:22 __ __ __ __ - __ __- __ __

Was extramedullary disease present?

yes no Unknown

23

Central nervous system

yes no

24

Cerebrospinal fluid (CSF)

Yes No

25

Parenchyma (brain)

Yes No

26

Skin

yes no

27

Soft tissue (soft tissue mass / granulocytic sarcoma)

yes no

28

Testes / ovaries

Yes No

29

Other site

yes no

30

Specify other site:31

Pre-HCT or Pre-Infusion Therapy Questions: 32 - 68

Was therapy given?

yes no

32

Line of Therapy (1) Questions: 33 - 68

Purpose of therapy33

Induction

Consolidation

Maintenance

treatment for disease relapse

Intrathecal therapy

yes no

34

Systemic therapy

yes no

35

Date therapy started

Known Unknown

36

Date started:37 __ __ __ __ - __ __- __ __

Date therapy stopped

Known Unknown

38

Date stopped:39 __ __ __ __ - __ __- __ __

Number of cycles

Known Unknown Not Applicable

40

Number of cycles:41

Specify systemic therapy: (check all that apply for this line of therapy)

Azacytidine

All-trans retinoic acid

Arsenic

Cladribine

Clofarabine

Cytarabine (Ara ­ C) ≤ 10 g/m2/cycle

cytarabine (Ara - C) > 10 g/m2/cycle

Daunorubicin

Decitabine

Etoposide

Fludarabine

Gemtuzumab

Idarubicin

Midostaurin

Mitoxantrone

Sorafenib

Thioguanine

Other systemic therapy

42

(Vidaza)

(Tretinoin)

(2-CDA, Leustatin)

(Cerubidine)

(Dacogen) 

(VP-16, VePesid)

(Fludara)

(Mylotarg)

(Idamycin)

(Novantrone)

(6-TG)

Specify months of therapy:43  (Azacytidine (Vidaza))

Specify months of therapy:44  (Decitabine (Dacogen))

Specify months of therapy:45 (Sorafenib)

Specify other systemic therapy:46

Radiation therapy

yes no

47

Date therapy started

Known Unknown

48

Date started:49 __ __ __ __ - __ __- __ __

Date therapy stopped

Known Unknown

50

Date stopped:51 __ __ __ __ - __ __- __ __

Central nervous system

yes no

52

Other site

yes no

53

Specify other site:54

Cellular therapy55

yes - Also complete Pre-CTED Form 4000

no

Best response to line of therapy56

Complete
remission
(CR)

– All of the following response criteria without progression for at least four weeks: < 5% blasts in the bone marrow, no blasts with Auer rods, 
no extramedullary disease (e.g., central nervous system or soft tissue involvement),  ANC of ≥ 1,000/µL, Platelets ≥ 100,000/ µL

Complete remission with incomplete hematologic recovery
(CRi)

- All CR criteria except for residual neutropenia (<1000/µl) and/or thrombocytopenia
(<100,000/µl)

No complete remission

Date assessed:57 __ __ __ __ - __ __- __ __

Was the recipient MRD negative following this line of therapy?

Yes No

58

Did the recipient relapse following this line of therapy?

yes no

59

Date of relapse:60 __ __ __ __ - __ __- __ __

Central nervous system

yes no

61

Cerebrospinal fluid (CSF)

Yes No

62

Parenchyma (brain)

Yes No

63

Skin

yes no

64

Soft tissue (soft tissue mass / granulocytic sarcoma)

yes no

65

Testes / ovaries

Yes No

66

Other site

yes no

67

Specify other site:68

Laboratory Studies at Last Evaluation Prior to the Start of the Preparative Regimen / Infusion Questions: 69 - 96

WBC

Known Unknown

69

70 x 109/L (x 103/mm3)

x 106/L

Date sample collected:71 __ __ __ __ - __ __- __ __

Blasts in blood

Known Unknown

72

73 %

Date sample collected:74 __ __ __ __ - __ __- __ __

Blasts in bone marrow

Known Unknown

75

76 %

Date sample collected:77 __ __ __ __ - __ __- __ __

Specify method of assessment

Flow cytometry Morphology

78

Was flow cytometry performed?

yes no Unknown

79

Blood

yes no

80

Date sample collected:81 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

82

Specify percent disease detected:83 %

Bone marrow

yes no

84

Date sample collected:85 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

86

Specify percent disease detected:87 %

Was extramedullary disease present?

yes no Unknown

88

Central nervous system

yes no

89

Cerebrospinal fluid (CSF)

Yes No

90

Parenchyma (brain)

Yes No

91

Skin

yes no

92

Soft tissue (soft tissue mass / granulocytic sarcoma)

yes no

93

Testes / ovaries

Yes No

94

Other site

yes no

95

Specify other site:96

First Name:

Last Name:

E-mail address:

Date: __ __ __ __ - __ __- __ __

Specify therapy for prior disease:

Specify site(s) of disease:

Specify site(s) of radiation therapy:

Specify site(s) of disease relapse:

Specify tissue and results at last evaluation prior to the start of the preparative regimen / infusion:

Specify site(s) of disease:

Center: CRID: 

Form 2010 R4.0: Acute Myelogenous Leukemia (AML) Pre-Infusion Data

CIBMTR Form 2010 revision 4.0 last updated Monday, July 17, 2017
Copyright(c) 2012 National Marrow Donor Program and

The Medical College of Wisconsin, Inc. All rights reserved. Page 3 / 5



Key Fields

Sequence Number:

Date Received: __ __ __ __ - __ __- __ __

CIBMTR Center Number:

CIBMTR Research ID:

Event date: __ __ __ __ - __ __- __ __

Subsequent Transplant or Cellular Therapy

Is this the report of a second or subsequent transplant or cellular therapy for the same disease?

Yes No

Disease Assessment at Diagnosis Questions: 1 - 13

Is the disease (AML) therapy related? (not MDS / MPN)

yes no Unknown

1

Specify prior disease2

Breast cancer

Hodgkin lymphoma

Non-Hodgkin lymphoma

Other disease (malignant or nonmalignant)

Specify other prior disease:3

Date of diagnosis of prior disease

Known Unknown

4

Date of diagnosis of prior disease:5 __ __ __ __ - __ __- __ __

Cytotoxic therapy

Yes No Unknown

6

Radiation

yes no Unknown

7

Other therapy (e.g. immunotherapy, cellular therapy, etc.)

yes no Unknown

8

Specify other therapy:9

Did the recipient have a documented antecedent hematologic disorder? (myelodysplastic syndrome or myeloproliferative neoplasm)

yes no Unknown

10

What was the date of diagnosis of antecedent hematologic disorder?11 __ __ __ __ - __ __- __ __

What was the classification of the antecedent hematologic disorder at diagnosis?12

Refractory cytopenia with unilineage dysplasia (RCUD) (includes refractory anemia (RA)) (51)

Refractory anemia with ringed sideroblasts (RARS) (55)

Refractory anemia with excess blasts-1 (RAEB-1) (61)

Refractory anemia with excess blasts-2 (RAEB-2) (62)

Refractory cytopenia with multilineage dysplasia (RCMD) (64)

Childhood myelodysplastic syndrome (Refractory cytopenia of childhood (RCC)) (68)

Myelodysplastic syndrome with isolated del(5q) (5q– syndrome) (66)

Myelodysplastic syndrome (MDS), unclassifiable (50)

Chronic neutrophilic leukemia (165)

Chronic eosinophilic leukemia, NOS (166)

Essential thrombocythemia (includes primary thrombocytosis, idiopathic thrombocytosis, hemorrhagic thrombocythemia) (58)

Polycythemia vera (PCV) (57)

Primary myelofibrosis (includes chronic idiopathic myelofibrosis (CIMF), angiogenic myeloid metaplasia (AMM), myelofibrosis/sclerosis with myeloid metaplasia
(MMM), idiopathic myelofibrosis) (167)

Myeloproliferative neoplasm (MPN), unclassifiable (60)

Chronic myelomonocytic leukemia (CMMoL) (54)

Juvenile myelomonocytic leukemia (JMML, JCML, JCMML) (no evidence of Ph1 or BCR/ABL) (36) Also complete CIBMTR Form 2015 - JMML

Atypical chronic myeloid leukemia, Ph-/bcr/abl- (CML, NOS) (45)

Atypical chronic myeloid leukemia, Ph-/bcr unknown (CML, NOS) (46)

Atypical chronic myeloid leukemia, Ph unknown/bcr- (CML, NOS) (48)

Atypical chronic myeloid leukemia, Ph unknown/bcr unknown (CML, NOS) (49)

Myelodysplastic / myeloproliferative neoplasm, unclassifiable (69) Also complete CIBMTR Form 2014 - MDS/MPN

Aplastic anemia (300) Also complete CIBMTR Form 2028 - APL

Fanconi anemia (311) Also complete CIBMTR Form 2029 – FA

Shwachman-Diamond (305)

Diamond-Blackfan anemia (pure red cell aplasia) (312)

Dyskeratosis congenita (307)

Other antecedent hematologic disorder

Specify other antecedent hematologic disorder:13

Laboratory Studies at Diagnosis Questions: 14 - 31

WBC

Known Unknown

14

15 x 109/L (x 103/mm3)

x 106/L

Date sample collected:16 __ __ __ __ - __ __- __ __

Blasts in blood

Known Unknown

17

18 %

Date sample collected:19 __ __ __ __ - __ __- __ __

Blasts in bone marrow

Known Unknown

20

21 %

Date sample collected:22 __ __ __ __ - __ __- __ __

Was extramedullary disease present?

yes no Unknown

23

Central nervous system

yes no

24

Cerebrospinal fluid (CSF)

Yes No

25

Parenchyma (brain)

Yes No

26

Skin

yes no

27

Soft tissue (soft tissue mass / granulocytic sarcoma)

yes no

28

Testes / ovaries

Yes No

29

Other site

yes no

30

Specify other site:31

Pre-HCT or Pre-Infusion Therapy Questions: 32 - 68

Was therapy given?

yes no

32

Line of Therapy (1) Questions: 33 - 68

Purpose of therapy33

Induction

Consolidation

Maintenance

treatment for disease relapse

Intrathecal therapy

yes no

34

Systemic therapy

yes no

35

Date therapy started

Known Unknown

36

Date started:37 __ __ __ __ - __ __- __ __

Date therapy stopped

Known Unknown

38

Date stopped:39 __ __ __ __ - __ __- __ __

Number of cycles

Known Unknown Not Applicable

40

Number of cycles:41

Specify systemic therapy: (check all that apply for this line of therapy)

Azacytidine

All-trans retinoic acid

Arsenic

Cladribine

Clofarabine

Cytarabine (Ara ­ C) ≤ 10 g/m2/cycle

cytarabine (Ara - C) > 10 g/m2/cycle

Daunorubicin

Decitabine

Etoposide

Fludarabine

Gemtuzumab

Idarubicin

Midostaurin

Mitoxantrone

Sorafenib

Thioguanine

Other systemic therapy

42

(Vidaza)

(Tretinoin)

(2-CDA, Leustatin)

(Cerubidine)

(Dacogen) 

(VP-16, VePesid)

(Fludara)

(Mylotarg)

(Idamycin)

(Novantrone)

(6-TG)

Specify months of therapy:43  (Azacytidine (Vidaza))

Specify months of therapy:44  (Decitabine (Dacogen))

Specify months of therapy:45 (Sorafenib)

Specify other systemic therapy:46

Radiation therapy

yes no

47

Date therapy started

Known Unknown

48

Date started:49 __ __ __ __ - __ __- __ __

Date therapy stopped

Known Unknown

50

Date stopped:51 __ __ __ __ - __ __- __ __

Central nervous system

yes no

52

Other site

yes no

53

Specify other site:54

Cellular therapy55

yes - Also complete Pre-CTED Form 4000

no

Best response to line of therapy56

Complete
remission
(CR)

– All of the following response criteria without progression for at least four weeks: < 5% blasts in the bone marrow, no blasts with Auer rods, 
no extramedullary disease (e.g., central nervous system or soft tissue involvement),  ANC of ≥ 1,000/µL, Platelets ≥ 100,000/ µL

Complete remission with incomplete hematologic recovery
(CRi)

- All CR criteria except for residual neutropenia (<1000/µl) and/or thrombocytopenia
(<100,000/µl)

No complete remission

Date assessed:57 __ __ __ __ - __ __- __ __

Was the recipient MRD negative following this line of therapy?

Yes No

58

Did the recipient relapse following this line of therapy?

yes no

59

Date of relapse:60 __ __ __ __ - __ __- __ __

Central nervous system

yes no

61

Cerebrospinal fluid (CSF)

Yes No

62

Parenchyma (brain)

Yes No

63

Skin

yes no

64

Soft tissue (soft tissue mass / granulocytic sarcoma)

yes no

65

Testes / ovaries

Yes No

66

Other site

yes no

67

Specify other site:68

Laboratory Studies at Last Evaluation Prior to the Start of the Preparative Regimen / Infusion Questions: 69 - 96

WBC

Known Unknown

69

70 x 109/L (x 103/mm3)

x 106/L

Date sample collected:71 __ __ __ __ - __ __- __ __

Blasts in blood

Known Unknown

72

73 %

Date sample collected:74 __ __ __ __ - __ __- __ __

Blasts in bone marrow

Known Unknown

75

76 %

Date sample collected:77 __ __ __ __ - __ __- __ __

Specify method of assessment

Flow cytometry Morphology

78

Was flow cytometry performed?

yes no Unknown

79

Blood

yes no

80

Date sample collected:81 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

82

Specify percent disease detected:83 %

Bone marrow

yes no

84

Date sample collected:85 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

86

Specify percent disease detected:87 %

Was extramedullary disease present?

yes no Unknown

88

Central nervous system

yes no

89

Cerebrospinal fluid (CSF)

Yes No

90

Parenchyma (brain)

Yes No

91

Skin

yes no

92

Soft tissue (soft tissue mass / granulocytic sarcoma)

yes no

93

Testes / ovaries

Yes No

94

Other site

yes no

95

Specify other site:96

First Name:

Last Name:

E-mail address:

Date: __ __ __ __ - __ __- __ __

Specify therapy for prior disease:

Specify site(s) of disease:

Specify site(s) of radiation therapy:

Specify site(s) of disease relapse:

Specify tissue and results at last evaluation prior to the start of the preparative regimen / infusion:

Specify site(s) of disease:

Center: CRID: 

Form 2010 R4.0: Acute Myelogenous Leukemia (AML) Pre-Infusion Data

CIBMTR Form 2010 revision 4.0 last updated Monday, July 17, 2017
Copyright(c) 2012 National Marrow Donor Program and

The Medical College of Wisconsin, Inc. All rights reserved. Page 4 / 5



Key Fields

Sequence Number:

Date Received: __ __ __ __ - __ __- __ __

CIBMTR Center Number:

CIBMTR Research ID:

Event date: __ __ __ __ - __ __- __ __

Subsequent Transplant or Cellular Therapy

Is this the report of a second or subsequent transplant or cellular therapy for the same disease?

Yes No

Disease Assessment at Diagnosis Questions: 1 - 13

Is the disease (AML) therapy related? (not MDS / MPN)

yes no Unknown

1

Specify prior disease2

Breast cancer

Hodgkin lymphoma

Non-Hodgkin lymphoma

Other disease (malignant or nonmalignant)

Specify other prior disease:3

Date of diagnosis of prior disease

Known Unknown

4

Date of diagnosis of prior disease:5 __ __ __ __ - __ __- __ __

Cytotoxic therapy

Yes No Unknown

6

Radiation

yes no Unknown

7

Other therapy (e.g. immunotherapy, cellular therapy, etc.)

yes no Unknown

8

Specify other therapy:9

Did the recipient have a documented antecedent hematologic disorder? (myelodysplastic syndrome or myeloproliferative neoplasm)

yes no Unknown

10

What was the date of diagnosis of antecedent hematologic disorder?11 __ __ __ __ - __ __- __ __

What was the classification of the antecedent hematologic disorder at diagnosis?12

Refractory cytopenia with unilineage dysplasia (RCUD) (includes refractory anemia (RA)) (51)

Refractory anemia with ringed sideroblasts (RARS) (55)

Refractory anemia with excess blasts-1 (RAEB-1) (61)

Refractory anemia with excess blasts-2 (RAEB-2) (62)

Refractory cytopenia with multilineage dysplasia (RCMD) (64)

Childhood myelodysplastic syndrome (Refractory cytopenia of childhood (RCC)) (68)

Myelodysplastic syndrome with isolated del(5q) (5q– syndrome) (66)

Myelodysplastic syndrome (MDS), unclassifiable (50)

Chronic neutrophilic leukemia (165)

Chronic eosinophilic leukemia, NOS (166)

Essential thrombocythemia (includes primary thrombocytosis, idiopathic thrombocytosis, hemorrhagic thrombocythemia) (58)

Polycythemia vera (PCV) (57)

Primary myelofibrosis (includes chronic idiopathic myelofibrosis (CIMF), angiogenic myeloid metaplasia (AMM), myelofibrosis/sclerosis with myeloid metaplasia
(MMM), idiopathic myelofibrosis) (167)

Myeloproliferative neoplasm (MPN), unclassifiable (60)

Chronic myelomonocytic leukemia (CMMoL) (54)

Juvenile myelomonocytic leukemia (JMML, JCML, JCMML) (no evidence of Ph1 or BCR/ABL) (36) Also complete CIBMTR Form 2015 - JMML

Atypical chronic myeloid leukemia, Ph-/bcr/abl- (CML, NOS) (45)

Atypical chronic myeloid leukemia, Ph-/bcr unknown (CML, NOS) (46)

Atypical chronic myeloid leukemia, Ph unknown/bcr- (CML, NOS) (48)

Atypical chronic myeloid leukemia, Ph unknown/bcr unknown (CML, NOS) (49)

Myelodysplastic / myeloproliferative neoplasm, unclassifiable (69) Also complete CIBMTR Form 2014 - MDS/MPN

Aplastic anemia (300) Also complete CIBMTR Form 2028 - APL

Fanconi anemia (311) Also complete CIBMTR Form 2029 – FA

Shwachman-Diamond (305)

Diamond-Blackfan anemia (pure red cell aplasia) (312)

Dyskeratosis congenita (307)

Other antecedent hematologic disorder

Specify other antecedent hematologic disorder:13

Laboratory Studies at Diagnosis Questions: 14 - 31

WBC

Known Unknown

14

15 x 109/L (x 103/mm3)

x 106/L

Date sample collected:16 __ __ __ __ - __ __- __ __

Blasts in blood

Known Unknown

17

18 %

Date sample collected:19 __ __ __ __ - __ __- __ __

Blasts in bone marrow

Known Unknown

20

21 %

Date sample collected:22 __ __ __ __ - __ __- __ __

Was extramedullary disease present?

yes no Unknown

23

Central nervous system

yes no

24

Cerebrospinal fluid (CSF)

Yes No

25

Parenchyma (brain)

Yes No

26

Skin

yes no

27

Soft tissue (soft tissue mass / granulocytic sarcoma)

yes no

28

Testes / ovaries

Yes No

29

Other site

yes no

30

Specify other site:31

Pre-HCT or Pre-Infusion Therapy Questions: 32 - 68

Was therapy given?

yes no

32

Line of Therapy (1) Questions: 33 - 68

Purpose of therapy33

Induction

Consolidation

Maintenance

treatment for disease relapse

Intrathecal therapy

yes no

34

Systemic therapy

yes no

35

Date therapy started

Known Unknown

36

Date started:37 __ __ __ __ - __ __- __ __

Date therapy stopped

Known Unknown

38

Date stopped:39 __ __ __ __ - __ __- __ __

Number of cycles

Known Unknown Not Applicable

40

Number of cycles:41

Specify systemic therapy: (check all that apply for this line of therapy)

Azacytidine

All-trans retinoic acid

Arsenic

Cladribine

Clofarabine

Cytarabine (Ara ­ C) ≤ 10 g/m2/cycle

cytarabine (Ara - C) > 10 g/m2/cycle

Daunorubicin

Decitabine

Etoposide

Fludarabine

Gemtuzumab

Idarubicin

Midostaurin

Mitoxantrone

Sorafenib

Thioguanine

Other systemic therapy

42

(Vidaza)

(Tretinoin)

(2-CDA, Leustatin)

(Cerubidine)

(Dacogen) 

(VP-16, VePesid)

(Fludara)

(Mylotarg)

(Idamycin)

(Novantrone)

(6-TG)

Specify months of therapy:43  (Azacytidine (Vidaza))

Specify months of therapy:44  (Decitabine (Dacogen))

Specify months of therapy:45 (Sorafenib)

Specify other systemic therapy:46

Radiation therapy

yes no

47

Date therapy started

Known Unknown

48

Date started:49 __ __ __ __ - __ __- __ __

Date therapy stopped

Known Unknown

50

Date stopped:51 __ __ __ __ - __ __- __ __

Central nervous system

yes no

52

Other site

yes no

53

Specify other site:54

Cellular therapy55

yes - Also complete Pre-CTED Form 4000

no

Best response to line of therapy56

Complete
remission
(CR)

– All of the following response criteria without progression for at least four weeks: < 5% blasts in the bone marrow, no blasts with Auer rods, 
no extramedullary disease (e.g., central nervous system or soft tissue involvement),  ANC of ≥ 1,000/µL, Platelets ≥ 100,000/ µL

Complete remission with incomplete hematologic recovery
(CRi)

- All CR criteria except for residual neutropenia (<1000/µl) and/or thrombocytopenia
(<100,000/µl)

No complete remission

Date assessed:57 __ __ __ __ - __ __- __ __

Was the recipient MRD negative following this line of therapy?

Yes No

58

Did the recipient relapse following this line of therapy?

yes no

59

Date of relapse:60 __ __ __ __ - __ __- __ __

Central nervous system

yes no

61

Cerebrospinal fluid (CSF)

Yes No

62

Parenchyma (brain)

Yes No

63

Skin

yes no

64

Soft tissue (soft tissue mass / granulocytic sarcoma)

yes no

65

Testes / ovaries

Yes No

66

Other site

yes no

67

Specify other site:68

Laboratory Studies at Last Evaluation Prior to the Start of the Preparative Regimen / Infusion Questions: 69 - 96

WBC

Known Unknown

69

70 x 109/L (x 103/mm3)

x 106/L

Date sample collected:71 __ __ __ __ - __ __- __ __

Blasts in blood

Known Unknown

72

73 %

Date sample collected:74 __ __ __ __ - __ __- __ __

Blasts in bone marrow

Known Unknown

75

76 %

Date sample collected:77 __ __ __ __ - __ __- __ __

Specify method of assessment

Flow cytometry Morphology

78

Was flow cytometry performed?

yes no Unknown

79

Blood

yes no

80

Date sample collected:81 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

82

Specify percent disease detected:83 %

Bone marrow

yes no

84

Date sample collected:85 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

86

Specify percent disease detected:87 %

Was extramedullary disease present?

yes no Unknown

88

Central nervous system

yes no

89

Cerebrospinal fluid (CSF)

Yes No

90

Parenchyma (brain)

Yes No

91

Skin

yes no

92

Soft tissue (soft tissue mass / granulocytic sarcoma)

yes no

93

Testes / ovaries

Yes No

94

Other site

yes no

95

Specify other site:96

First Name:

Last Name:

E-mail address:

Date: __ __ __ __ - __ __- __ __

Specify therapy for prior disease:

Specify site(s) of disease:

Specify site(s) of radiation therapy:

Specify site(s) of disease relapse:

Specify tissue and results at last evaluation prior to the start of the preparative regimen / infusion:

Specify site(s) of disease:

Center: CRID: 

Form 2010 R4.0: Acute Myelogenous Leukemia (AML) Pre-Infusion Data

CIBMTR Form 2010 revision 4.0 last updated Monday, July 17, 2017
Copyright(c) 2012 National Marrow Donor Program and

The Medical College of Wisconsin, Inc. All rights reserved. Page 5 / 5